Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Trial Identifier: D3610C00001
Sponsor: AstraZeneca
NCTID:: NCT01226316
Start Date: December 2010
Primary Completion Date: April 2019
Study Completion Date: December 2023
Condition: Breast Cancer; Cancer - Other; Endometriosis; Ovarian Cancer; Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Danish Translation
Spanish Translation
French Translation
Italian Translation
Japanese Translation
Dutch Translation

Trial Locations

Country Location
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H4A 3T2
DK København Ø, DK, 2100
ES Madrid, ES, 28041
ES Madrid, ES, 08035
ES Valencia, ES, 46010
FR Pierre Benite CEDEX, FR, 69310
FR Villejuif, FR, 94805
GB Manchester, GB, M20 4BX
GB Sutton, GB, SM2 5PT
IT Milan, IT, 20141
IT Napoli, IT, 80131
IT Prato, IT, 59100
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
JP Koto-ku, JP, 135-8550
JP Sapporo-shi, JP, 060-8638
NL Amsterdam, NL, 1066 CX
SG Singapore, SG, 119228
US, CA Los Angeles, CA, US, 90089
US, CA Stanford, CA, US, 94304
US, CA West Hollywood, CA, US, 90048
US, CO Aurora, CO, US, 80045
US, MA Boston, MA, US, 02215
US, NY New York, NY, US, 10022
US, OK Oklahoma City, OK, US, 73104
US, OR Portland, OR, US, 97239
US, SC Charleston, SC, US, 29425
US, TN Nashville, TN, US, 37203
US, TN Nashville, TN, US, 37204
US, TX Houston, TX, US, 77030